Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | ABBV |
---|---|---|
09:32 ET | 3073 | 170.76 |
09:34 ET | 69200 | 170.715 |
09:36 ET | 9485 | 171.555 |
09:38 ET | 6697 | 171.22 |
09:39 ET | 8785 | 171.245 |
09:41 ET | 8133 | 171.255 |
09:43 ET | 8394 | 171.365 |
09:45 ET | 6675 | 171.315 |
09:48 ET | 8164 | 170.99 |
09:50 ET | 24036 | 170.98 |
09:52 ET | 6250 | 171.04 |
09:54 ET | 22668 | 170.795 |
09:56 ET | 12813 | 170.935 |
09:57 ET | 6723 | 170.775 |
09:59 ET | 8264 | 170.89 |
10:01 ET | 8838 | 170.89 |
10:03 ET | 8996 | 170.59 |
10:06 ET | 12627 | 170.34 |
10:08 ET | 10512 | 170.35 |
10:10 ET | 7500 | 170.41 |
10:12 ET | 5086 | 170.26 |
10:14 ET | 6989 | 170.175 |
10:15 ET | 14862 | 170.04 |
10:17 ET | 8233 | 170.07 |
10:19 ET | 16249 | 170 |
10:21 ET | 5040 | 169.975 |
10:24 ET | 5239 | 170.025 |
10:26 ET | 5441 | 170.1946 |
10:28 ET | 5063 | 170.055 |
10:30 ET | 3201 | 170.06 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
AbbVie Inc | 302.2B | 50.7x | -6.05% |
Merck & Co Inc | 333.1B | 146.0x | -43.23% |
AstraZeneca PLC | 246.9B | 38.9x | +17.52% |
Novartis AG | 234.8B | 24.2x | -5.59% |
Roche Holding AG | 228.1B | 17.6x | +3.28% |
Pfizer Inc | 155.4B | -446.6x | -7.10% |
AbbVie Inc. is a diversified research-based biopharmaceutical company. The Company is engaged in the research and development, manufacturing, commercialization and sale of medicines and therapies. It offers products in therapeutic categories, including immunology, which include Humira, Skyrizi and Rinvoq; oncology, which include Imbruvica, Venclexta/Venclyxto, Epkinly and Elahere; aesthetics products, which include Botox Cosmetic, The Juvederm Collection of Fillers and others; neuroscience, which include Botox Therapeutic, Vraylar, Duopa and Duodopa, Ubrelvy and Qulipta; eye care, which consists of Ozurdex, Lumigan/Ganfort, Alphagan/Combigan, Restasis and Other eye care, and other key products, which include Mavyret/Maviret, Creon, Lupron, Linzess/Constella and Synthroid. It also offers investigational asset named NX-13, oral NLRX1 agonist (a member of the NOD-like receptor family), which is in Phase II for the treatment of ulcerative colitis (UC) and Crohn's disease (CD).
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $302.2B |
---|---|
Revenue (TTM) | $54.4B |
Shares Outstanding | 1.8B |
Dividend Yield | 3.65% |
Annual Dividend Rate | 6.2000 USD |
Ex-Dividend Date | 07-15-24 |
Pay Date | 08-15-24 |
Beta | 0.62 |
EPS | $3.36 |
Book Value | $5.87 |
P/E Ratio | 50.7x |
Price/Sales (TTM) | 5.6 |
Price/Cash Flow (TTM) | 20.6x |
Operating Margin | 23.50% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.